{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:28:56Z","timestamp":1791898136213,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Overactive bladder (OAB) is defined as urinary urgency accompanied by frequency and nocturia, with or without urge urinary incontinence (UUI). Vibegron, a selective \u03b2<jats:sub>3<\/jats:sub>-adrenergic receptor agonist approved in the US in December 2020, demonstrated efficacy in reducing symptoms of OAB and was safe and well tolerated in the 12-week EMPOWUR trial and its 40-week, double-blind extension trial. The goal of the COMPOSUR study is to evaluate vibegron in a real-world setting to assess patient treatment satisfaction, tolerability, safety, duration of treatment, and persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a 12-month, prospective, observational, real-world study, with an optional 12-month extension to 24\u00a0months, in the US assessing adults\u2009\u2265\u200918\u00a0years old starting a new course of vibegron. Patients must be previously diagnosed with OAB with or without UUI, symptomatic for\u2009\u2265\u20093\u00a0months before enrollment, and receive prior treatment with an anticholinergic, with mirabegron, or with a combination of an anticholinergic and mirabegron. Enrollment is performed by the investigator following exclusion and inclusion criteria guided by US product labeling, reinforcing a real-world approach. Patients complete the OAB Satisfaction with Treatment Questionnaire (OAB-SAT-q) monthly and the OAB Questionnaire short form (OAB-q-SF) and Work Productivity and Activity Impairment Questionnaire (WPAI:US) at baseline and monthly for 12\u00a0months. Patients are followed up via phone call, in-person visits, or telehealth (ie, virtual) visits. The primary endpoint is patient treatment satisfaction as determined by the OAB-SAT-q satisfaction domain score. Secondary endpoints include percent positive responses to individual OAB-SAT-q questions, additional OAB-SAT-q domain scores, and safety. Exploratory endpoints include adherence and persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>OAB leads to a significant decrease in quality of life, as well as impairment of work activities and productivity. Persistence with OAB treatments can be challenging, often due to lack of efficacy and adverse effects. COMPOSUR is the first study to provide long-term, prospective, pragmatic treatment data for vibegron in the US and the resultant effect on quality of life among patients with OAB in a real-world clinical setting.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov identifier: NCT05067478; registered: October 5, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-023-01240-7","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:03:04Z","timestamp":1682348584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder"],"prefix":"10.1186","volume":"23","author":[{"given":"Roger R.","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Abedinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. American Urological Association; 2019.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"6","key":"1240_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"4","key":"1240_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","volume":"7","author":"KS Coyne","year":"2004","unstructured":"Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455\u201363.","journal-title":"Value Health"},{"issue":"11","key":"1240_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"1","key":"1240_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/nau.23277","volume":"37","author":"IGR Melotti","year":"2018","unstructured":"Melotti IGR, Juliato CRT, Tanaka M, Riccetto CLZ. Severe depression and anxiety in women with overactive bladder. Neurourol Urodyn. 2018;37(1):223\u20138.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1240_CR6","first-page":"406","volume":"22","author":"A Yehoshua","year":"2016","unstructured":"Yehoshua A, Chancellor M, Vasavada S, Malone DC, Armstrong EP, Joshi M, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406\u201313.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1240_CR7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/nau.23513","volume":"37","author":"E Durden","year":"2018","unstructured":"Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States. Neurourol Urodyn. 2018;37(5):1641\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"1240_CR8","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/nau.24527","volume":"39","author":"T Soda","year":"2020","unstructured":"Soda T, Tashiro Y, Koike S, Ikeuchi R, Okada T. Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn. 2020;39(8):2527\u201334.","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"1240_CR9","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276\u201382.","journal-title":"BJU Int"},{"issue":"1 Pt 2","key":"1240_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jfma.2018.05.006","volume":"118","author":"CC Wang","year":"2019","unstructured":"Wang CC, Kuo HC. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. J Formos Med Assoc. 2019;118(1 Pt 2):279\u201384.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1240_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","volume":"111","author":"A Mohee","year":"2013","unstructured":"Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106\u201313.","journal-title":"BJU Int"},{"issue":"4","key":"1240_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/luts.12382","volume":"13","author":"KV Carlson","year":"2021","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425\u201334.","journal-title":"Low Urin Tract Symptoms"},{"issue":"6","key":"1240_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/JU.0000000000001440","volume":"205","author":"YS Song","year":"2021","unstructured":"Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6):1595\u2013604.","journal-title":"J Urol"},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/PPA.S178668","volume":"12","author":"A Athavale","year":"2018","unstructured":"Athavale A, Gooch K, Walker D, Suh M, Scaife J, Haber A, et al. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naive overactive bladder patients in the US. Patient Prefer Adherence. 2018;12:2139\u201352.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1240_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"SD Edmondson","year":"2016","unstructured":"Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, et al. Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609\u201323.","journal-title":"J Med Chem"},{"issue":"2","key":"1240_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"5","key":"1240_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421\u20139.","journal-title":"J Urol"},{"key":"1240_CR18","unstructured":"Urovant Sciences. GEMTESA\u00ae (vibegron). Full Prescribing Information. Irvine, CA: 2020."},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.urology.2020.11.065","volume":"153","author":"B Shiff","year":"2021","unstructured":"Shiff B, Frankel J, Oake J, Blachman-Braun R, Patel P. Patient satisfaction with telemedicine appointments in an academic andrology-focused urology practice during the COVID-19 pandemic. Urology. 2021;153:35\u201341.","journal-title":"Urology"},{"issue":"5","key":"1240_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/nau.20672","volume":"28","author":"MK Margolis","year":"2009","unstructured":"Margolis MK, Fox KM, Cerulli A, Ariely R, Kahler KH, Coyne KS. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). Neurourol Urodyn. 2009;28(5):416\u201322.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"1240_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/nau.22559","volume":"34","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255\u201363.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1240_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1240_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"2","key":"1240_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cpt.1086","volume":"104","author":"H Yuan","year":"2018","unstructured":"Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, et al. Real-world evidence: what it is and what it can tell us according to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin Pharmacol Ther. 2018;104(2):239\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1240_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/03007995.2017.1419170","volume":"34","author":"R Freeman","year":"2018","unstructured":"Freeman R, Foley S, Rosa Arias J, Vicente E, Grill R, Kachlirova Z, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785\u201393.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1240_CR26","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/ijcp.12450","volume":"68","author":"T Schneider","year":"2014","unstructured":"Schneider T, Arumi D, Crook TJ, Sun F, Michel MC. An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. Int J Clin Pract. 2014;68(9):1074\u201380.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"1240_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/luts.12148","volume":"10","author":"Y Nozawa","year":"2018","unstructured":"Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study. Low Urin Tract Symptoms. 2018;10(2):122\u201330.","journal-title":"Low Urin Tract Symptoms"},{"issue":"11","key":"1240_CR28","doi-asserted-by":"publisher","first-page":"e21875","DOI":"10.2196\/21875","volume":"22","author":"JM Dubin","year":"2020","unstructured":"Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, et al. Telemedicine usage among urologists during the COVID-19 pandemic: cross-sectional study. J Med Internet Res. 2020;22(11):e21875.","journal-title":"J Med Internet Res"},{"issue":"1","key":"1240_CR29","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.9778\/cmajo.20200311","volume":"9","author":"RS Bhatia","year":"2021","unstructured":"Bhatia RS, Chu C, Pang A, Tadrous M, Stamenova V, Cram P. Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. CMAJ Open. 2021;9(1):E107\u201314.","journal-title":"CMAJ Open"},{"issue":"6","key":"1240_CR30","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00345-020-03432-4","volume":"39","author":"U Pinar","year":"2021","unstructured":"Pinar U, Anract J, Perrot O, Tabourin T, Chartier-Kastler E, Parra J, et al. Preliminary assessment of patient and physician satisfaction with the use of teleconsultation in urology during the COVID-19 pandemic. World J Urol. 2021;39(6):1991\u20136.","journal-title":"World J Urol"},{"key":"1240_CR31","unstructured":"American Urological Association. The state of urology workforce and practice in the United States. AUAnet.org: American Urological Association; 2021."},{"issue":"34","key":"1240_CR32","doi-asserted-by":"publisher","first-page":"e12824","DOI":"10.1111\/ijcp.12824","volume":"71","author":"D Sussman","year":"2017","unstructured":"Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71(34):e12824.","journal-title":"Int J Clin Pract."},{"issue":"11","key":"1240_CR33","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s12325-019-01098-y","volume":"36","author":"M Ali","year":"2019","unstructured":"Ali M, Grogan S, Powell S, Staniford L, Nazir J, Landeira M, et al. Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care. Adv Ther. 2019;36(11):3110\u201322.","journal-title":"Adv Ther"},{"issue":"2","key":"1240_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MBP.0000000000000572","volume":"27","author":"MA Weber","year":"2022","unstructured":"Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd PN Jr, White WB. Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Press Monit. 2022;27(2):128\u201334.","journal-title":"Blood Press Monit"},{"issue":"3","key":"1240_CR35","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bju.12505","volume":"113","author":"DH Tang","year":"2014","unstructured":"Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int. 2014;113(3):484\u201391.","journal-title":"BJU Int"},{"issue":"2","key":"1240_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12325-021-01972-8","volume":"39","author":"J Frankel","year":"2022","unstructured":"Frankel J, Staskin D, Varano S, Kennelly M, Newman DK, Rosenberg MT, et al. Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR. Adv Ther. 2022;39(2):959\u201370.","journal-title":"Adv Ther"},{"issue":"5","key":"1240_CR37","doi-asserted-by":"publisher","first-page":"e13937","DOI":"10.1111\/ijcp.13937","volume":"75","author":"J Frankel","year":"2021","unstructured":"Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5):e13937.","journal-title":"Int J Clin Pract"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-023-01240-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T03:37:12Z","timestamp":1682393832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-023-01240-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1186\/s12894-023-01240-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study will be conducted in compliance with International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\/Good Clinical Practice guidelines. Investigators will receive institutional review board, research ethics board, or independent ethics committee approval before the initiation of the study. All patients will provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RRD is a consultant for Urovant Sciences. ESR has a relationship with Ion Channel Innovations, LLC; is a consultant for Urovant Sciences and Hologic; and has received research funding from Allergan, Medtronics, and Uromedica. MJK is a consultant for Allergan, Astellas, Boston Scientific, Coloplast, Laborie, and Urovant Sciences and has received grant or research study funding from Allergan, Axonics, Boston Scientific, Coloplast, Cook Myosite, Dignify Therapeutics, EBT Medical, and FemPulse. DKN is an editor at Digital Science Press; consultant for Cosm Medical, Convatec, and Urovant Sciences; and has received funding from the National Institutes of Health and the Society of Urologic Nurses and Associates. LA, ET, and DS are employees of Urovant Sciences. CH-M was an employee of Urovant Sciences at the time the study protocol was developed. MTR is a consultant and speaker for Urovant Sciences; a consultant and speaker for Astellas Pharma; and a consultant for Ferring.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}